Immunovia AB (FRA:1YR)
€ 0.0338 0.0013 (4%) Market Cap: 8.99 Mil Enterprise Value: 6.59 Mil PE Ratio: 0 PB Ratio: 2.83 GF Score: 42/100

Immunovia AB (publ) Announces Completion of Analysis from the IMMray™ PanCan-d Verification Study - Conference Call Transcript

Oct 26, 2020 / 03:30PM GMT
Julie Silber;publ;Director of IR
Immunovia AB

()-

Hello, and welcome to Immunovia's update call on the verification and validation studies. This is Julie Silber, Director of IR for Immunovia, and I will be the moderator for today's call. Please note, this conference is being recorded, and for the duration of the call, your lines will be on listen only.

On the call with me today is CEO, Mats Grahn; and incoming CEO, Patrik Dahlen. After a brief statement, we will open up for Q&A. (Operator Instructions)

Before we begin, a quick reminder to our listeners. During today's webinar, management may make forward-looking statements that involve known and unknown risks, uncertainties and other important factors beyond the company's control that could cause the company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot